08:51 AM EDT, 05/06/2024 (MT Newswires) -- VYNE Therapeutics ( VYNE ) said Monday the US Food and Drug Administration has cleared its Investigational New Drug Application for VYN202, its potential autoimmune disease treatment

Vyne said it plans to initiate a first-in-human phase 1a trial of VYN202 in healthy volunteers in Q2 and report top line results from the trial in the second half of 2024. The study is expected to enroll approximately 64 adults.

VYN202 is an orally administered small-molecule BD2-selective BET inhibitor.

Vyne shares were up nearly 17% in recent Monday premarket activity.

Price: 3.0600, Change: +0.44, Percent Change: +16.79